Thank you, Mr. Chairman.
These reductions will result in significant savings to the healthcare system and patients as the biosimilar market matur...
If we get a whole rash of State laws that erect barriers it doesn't really matter what education you do if the law preve...
I know this is an issue that doesn't necessarily fit natural to Congress to be funding physician and provider education,...
We talked about the certainty that the industry needs to start populating the field with more biosimilars.
I hope that we can talk about that today.
This increased cost is born by our healthcare system as a whole, but more specifically by patients as more and more insu...
We can do all of this work on trying to make sure that we approve biosimilars, but if they're not actually getting presc...
It took us a long time to educate both providers and patients about chemical generics.
I did not see it while I was there.
I think that there is a potentially really significantly high cost to the United States compared to what I would suggest...